Spicing up pharma specialty news
We can only close our eyes and imagine the hilarity that ensured when in-Pharma Technologist.com Katrina Megget flashed this pun-in-cheek headline by her editor: ”Inhaler solution to premature ejaculation hasn’t come too soon.” No doubt it was the highlight of their month. Curious readers will find that Ms. Megget reserved some levity for the story itself, noting that Vectura’s Phase 2 inhaled dry powder (VR776) worked quickly, allowing spontaneity around the “naughty rendezvous” (curiously, this is also how sponsors refer to the FDA’s end-of-phase 2 meeting).
I empathize with Ms. Megget’s plight. It’s hard difficult to stay entirely serious when contemplating this topic. Only the sturdiest most professional of commentators have the strength of will to avoid the obvious cheap jokes. For a no-nonsense, quick-and-dirty, in-and-out-and-off-we-go take on this issue, see my 2005 commentary on J&J’s now abandoned but memorably noble R&D efforts in the war against premature ejaculation.
